A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.
A large and heterogenous group of fungi whose common characteristic is the absence of a sexual state. Many of the pathogenic fungi in humans belong to this group.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
The transference of a heart from one human or animal to another.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
Enzymes that catalyze the reversible reduction of alpha-carboxyl group of 3-hydroxy-3-methylglutaryl-coenzyme A to yield MEVALONIC ACID.
7-carbon saturated monocarboxylic acids.

SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. (1/866)

Resistance to chemotherapy is the major cause of cancer treatment failure. Insight into the mechanism of action of agents that modulate multidrug resistance (MDR) is instrumental for the design of more effective treatment modalities. Here we show, using KB-V-1 MDR human epidermoid carcinoma cells and [3H]palmitic acid as metabolic tracer, that the MDR modulator SDZ PSC 833 (PSC 833) activates ceramide synthesis. In a short time course experiment, ceramide was generated as early as 15 min (40% increase) after the addition of PSC 833 (5.0 microM), and by 3 h, [3H]ceramide was >3-fold that of control cells. A 24-h dose-response experiment showed that at 1.0 and 10 microM PSC 833, ceramide levels were 2.5- and 13.6-fold higher, respectively, than in untreated cells. Concomitant with the increase in cellular ceramide was a progressive decrease in cell survival, suggesting that ceramide elicited a cytotoxic response. Analysis of DNA in cells treated with PSC 833 showed oligonucleosomal DNA fragmentation, characteristic of apoptosis. The inclusion of fumonisin B1, a ceramide synthase inhibitor, blocked PSC 833-induced ceramide generation. Assessment of ceramide mass by TLC lipid charring confirmed that PSC 833 markedly enhanced ceramide synthesis, not only in KB-V-1 cells but also in wild-type KB-3-1 cells. The capacity of PSC 833 to reverse drug resistance was demonstrated with vinblastine. Whereas each agent at a concentration of 1.0 microM reduced cell survival by approximately 20%, when PSC 833 and vinblastine were coadministered, cell viability fell to zero. In parallel experiments measuring ceramide metabolism, it was shown that the PSC 833/vinblastine combination synergistically increased cellular ceramide levels. Vinblastine toxicity, also intensified by PSC 833 in wild-type KB-3-1 cells, was as well accompanied by enhanced ceramide formation. These data demonstrate that PSC 833 has mechanisms of action in addition to P-glycoprotein chemotherapy efflux pumping.  (+info)

Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. (2/866)

Class I P-glycoproteins (Pgp) confer multidrug resistance in tumors, but the physiologic function of Pgp in normal tissues remains uncertain. In cells derived from tissues that normally express Pgp, recent data suggest a possible role for Pgp in cholesterol trafficking from the plasma membrane to the endoplasmic reticulum. We investigated the esterification of plasma membrane cholesterol under basal conditions and in response to sphingomyelinase treatment in transfected and drug-selected cell lines expressing differing amounts of functional class I Pgp. Compared with parental NIH 3T3 fibroblasts, cells transfected with human multidrug resistance (MDR1) Pgp esterified more cholesterol both without and with sphingomyelinase. Esterification also was greater in drug-selected Dox 6 myeloma cells than parental 8226 cells, which express low and non-immunodetectable amounts of Pgp, respectively. However, no differences in total plasma membrane cholesterol were detected. Transfection of fibroblasts with the multidrug resistance-associated protein (MRP) did not alter esterification, showing that cholesterol trafficking was not generally affected by ATP-binding cassette transporters. Steroidal (progesterone, dehydroepiandrosterone) and non-steroidal antagonists (verapamil, PSC 833, LY335979, and GF120918) were evaluated for effects on both cholesterol trafficking and the net content of 99mTc-Sestamibi, a reporter of drug transport activity mediated by Pgp. In Pgp-expressing cells treated with nonselective and selective inhibitors, both the kinetics and efficacy of inhibition of cholesterol esterification differed from the antagonism of drug transport mediated by Pgp. Thus, although the data show that greater expression of class I Pgp within a given cell type is associated with enhanced esterification of plasma membrane cholesterol in support of a physiologic function for Pgp in facilitating cholesterol trafficking, the molecular mechanism is dissociated from the conventional drug transport activity of Pgp.  (+info)

Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents. (3/866)

Because 99mTc-sestamibi (MIBI) appears to be a potent candidate for multidrug resistance (MDR) evaluation in tumors, its cellular uptake should be similar to that of 3H-daunomycin in a variety of conditions of expression and inhibition of MDR activity. METHODS: We used a human rhinopharyngeal carcinoma cell line (KB-3-1) and its MDR variant (KB-A1). Cells were incubated 2 h with 99mTc-MIBI and 3H-daunomycin under control conditions or in the presence of a reversing agent such as verapamil (10 pmol/L), PSC833 (1 micromol/L) or S9788 (5 micromol/L). RESULTS: Relative to the KB-3-1-sensitive cells, accumulations of 99mTc-MIBI and 3H-daunomycin were reduced to 31% +/- 5% and 36% +/- 11% (P < 0.001 for both) in KB-A1-resistant cells. In sensitive cells, accumulation of both agents was increased by verapamil and PSC833 (range 115%-140%; P < 0.05) but not by S9788. In KB-A1 cells, only S9788 significantly increased the cellular uptake of 99mTc-MIBI (138% +/- 25%; P < 0.01), whereas the intracellular uptake of 3H-daunomycin was markedly increased with the three reversing agents (up to 311% +/- 37% with S9788; P < 0.001). With this last treatment, uptake of 3H-daunomycin in KB-A1 cells nearly returned to its basal level in sensitive cells. CONCLUSION: 99mTc-MIBI monitors the MDR phenotype of tumor cells effectively but responds to reversing agents differently than 3H-daunomycin.  (+info)

Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. (4/866)

PSC 833 has been used to overcome the phenomenon of multidrug resistance by inhibiting the P-glycoprotein (P-gp)-mediated efflux of antitumor drugs from tumor cells. Because P-gp expressed in several normal tissues may affect the disposition of its substrates, we examined the dose-dependent effect of PSC 833 on the disposition of vincristine (VCR) and digoxin (DGX) in rats. One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg. Three milligrams per kilogram PSC 833 significantly reduced the renal clearance of VCR by 30% but did not affect that of DGX significantly. The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg. The differential effect of PSC 833 on the disposition of VCR and DGX may be ascribed to the different degree of contribution of P-gp to the disposition of these ligands.  (+info)

Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. (5/866)

The mitochondrial permeability transition pore is an inducer of cell death. During the reperfusion phase after cerebral ischemia, calcium accumulates in mitochondria, and a burst of free radical formation occurs, conditions that favor the activation of the mitochondrial permeability transition pore. Here the authors demonstrate that a blocker of the mitochondrial permeability transition pore, the nonimmunosuppressive cyclosporin A analogue N-methyl-Val-4-cyclosporin A (10 mg/kg intraperitoneally), administered during reperfusion and at 24 hours of reperfusion, diminishes infarct size in a rat model of transient focal ischemia of 2 hours' duration. The mitochondrial permeability transition pore may be an important target for drugs against stroke.  (+info)

Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore. (6/866)

We have studied the effects of GD3 ganglioside on mitochondrial function in isolated mitochondria and intact cells. In isolated mitochondria, GD3 ganglioside induces complex changes of respiration that depend on the substrate being oxidized. However, these effects are secondary to opening of the cyclosporin A-sensitive permeability transition pore and to the ensuing swelling and cytochrome c depletion rather than to an interaction with the respiratory chain complexes. By using a novel in situ assay based on the fluorescence changes of mitochondrially entrapped calcein (Petronilli, V., Miotto, G., Canton, M., Colonna, R., Bernardi, P., and Di Lisa, F. (1999) Biophys. J. 76, 725-734), we unequivocally show that GD3 ganglioside also induces the mitochondrial permeability transition in intact cells and that this event precedes apoptosis. The mitochondrial effects of GD3 ganglioside are selective, in that they cannot be mimicked by either GD1a or GM3 gangliosides, and they are fully sensitive to cyclosporin A, which inhibits both the mitochondrial permeability transition in situ and the onset of apoptosis induced by GD3 ganglioside. These results provide compelling evidence that opening of the permeability transition pore is causally related to apoptosis.  (+info)

Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells. (7/866)

Cyclosporin (CsA) is widely used in the treatment of renal disease and transplantation, which are often complicated by alterations of lipid metabolism. Both chronic administration of CsA and hyperlipidaemia have been shown to evoke an early macrophage influx and have progressively led to glomerular and interstitial sclerosis. MCP-1 is the major monocyte chemoattractant secreted by stimulated mesangial cells and TGF-beta 1 is a key mediator of fibrogenesis in chronic progressive renal fibrosis. Thus, the combined effect of CsA and low-density lipoprotein (LDL) on the gene and protein expression of MCP-1 and TGF-beta 1 in cultured human mesangial cells (HMC) was explored. Both agents induced an early and persistent increase of MCP-1 and TGF-beta 1 mRNA levels and protein release. The simultaneous addition of CsA and LDL did not display any additive effect on target gene expression, but it caused a synergistic effect on MCP-1 and TGF-beta 1 protein secretion into culture medium. On the other hand, CsA and LDL had different effects on cell proliferation: the latter increased DNA synthesis, whereas CsA inhibited both spontaneous and mitogen-stimulated mesangial cell growth. The study concludes that CsA and LDL display an additive effect on TGF-beta 1 and MCP-1 synthesis and release by HMC, thus possibly co-operating to induce an early macrophage influx and the subsequent mesangial expansion and increased extracellular matrix deposition. However, in contrast they seem to modulate HMC proliferation differently, which is a further critical event intimately involved in the development of glomerulosclerosis.  (+info)

Thapsigargin directly induces the mitochondrial permeability transition. (8/866)

High concentrations of thapsigargin (TG) have been used to study the process of necrotic cell death, which involves mitochondria in the cell rapidly undergoing the mitochondrial permeability transition (MPT). We therefore investigated the effects of TG on MPT in isolated liver and heart mitochondria. Using a matrix swelling assay in combination with a novel enzymatic method based on inner membrane permeability to citrate synthase substrates, TG induced MPT in a concentration-dependent manner, independent of extramitochondrial [Ca2+] and inhibitable by cyclosporin A. Evidence from alamethicin-permeabilized mitochondria suggests that TG induces MPT by causing Ca2+ release from mitochondrial matrix Ca2+-binding sites. These findings suggest that the MPT-inducing effect of TG may contribute to its pro-necrotic and pro-apoptotic effects in various cell types.  (+info)

Cyclosporin A (ciclosporin) Cyclosporin B Cyclosporin C Cyclosporin D Cyclosporin E Cyclosporin F Cyclosporin G Lawen A ( ... The cyclosporins are a group of macrolides isolated from fungi and used as immunosuppresant drugs, for example after transplant ... They are nonribosomal peptide synthesized by cyclosporin synthetase. ... October 2015). "Biosynthesis of cyclosporins and other natural peptidyl prolyl cis/trans isomerase inhibitors". Biochimica et ...
"Definition of cyclosporin". Lexico.com. Oxford University Press. 2020. Archived from the original on November 24, 2020. ...
So also are the immunosuppressant macrolides, the cyclosporins. The cholesterol-lowering drugs, the statins, were initially ...
A new cyclosporin side-effect]". Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete. 46 (12): 841-6 ...
"Dogger Bank Itch and cyclosporin". Journal of Dermatological Treatment. 12 (1): 23-24. doi:10.1080/095466301750163536. PMID ...
In 1972, Borel was involved in the discovery of the immunosuppressive effects of cyclosporin (Sandoz called Sandimmun), which ... Heusler, Karl (2001). "The controversial early history of cyclosporin". Swiss Medical Weekly. 131 (21-22): 299-302. PMID ... is a Belgian microbiologist and immunologist who is considered one of the discoverers of cyclosporin. Borel studied at the ...
Cyclosporin A has been shown to decrease cardiac hypertrophy by affecting cardiac myocytes in many ways. Cyclosporin A binds to ... Cyclosporin is synthesized by a nonribosomal peptide synthetase, cyclosporin synthetase. The enzyme contains an adenylation ... Cyclosporin A also inhibits the phosphatase calcineurin pathway (14). Inhibition of this pathway has been shown to decrease ... CypD is a protein within the MPTP that acts as a gate; binding by cyclosporin A decreases the amount of inappropriate opening ...
Also like cyclosporin, it has a wide range of interactions. Tacrolimus is primarily metabolised by the cytochrome P450 system ... Although this activity is similar to that of cyclosporin, the incidence of acute rejection is reduced by tacrolimus use over ... Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL (October 2006). McAlister V (ed.). "Cyclosporin versus ... Pritchard DI (May 2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery ...
They also allow transition to cyclosporin therapy. Polyclonal antibodies inhibit T lymphocytes and cause their lysis, which is ...
In 1994, the company began developing Cyclosporin. The company broke the ₩100,000,000,000 barrier in sales in 1997. The company ...
Cyclosporin A is a chemical inducer of dimerization (CID) of cyclophilin. This first bump-and-hole pair was engineered to ... The bumped cyclosporin A was found to interact efficiently with the hole-modified cyclophilin mutant, but not endogenous ... The first bump-and-hole pair, developed by Stuart Schreiber and colleagues, was a bumped cyclosporin A small-molecule with an ... Belshaw, Peter J.; Schreiber, Stuart L. (February 1997). "Cell-Specific Calcineurin Inhibition by a Modified Cyclosporin". ...
Rojnuckarin, P.; Nakorn, TN.; Assanasen, T.; Wannakrairot, P.; Intragumtornchai, T. (Mar 2007). "Cyclosporin in subcutaneous ...
Borel JF, Feurer C, Gubler HU, Stähelin H (1976). "Biological effects of cyclosporin A: a new antilymphocytic agent". Agents ... Comment on „Hartmann Stahelin (1925-2011) and the Contested Hidtory of Cyclosporin A. Clin Transplant 2013. DOI 10.1111/ctr. ... Stähelin HF (1996). "The history of cyclosporin A (Sandimmune) revisited: another point of view". Experientia. 52 (1): 5-13. ...
"Liver transplantation with use of cyclosporin a and prednisone". N. Engl. J. Med. 305 (5): 266-9. doi:10.1056/ ...
Other effective systemic approaches include: methotrexate, cyclosporin and corticosteroids. There are also reports that the ...
These two families are: "cyclosporin-binding cyclophilins (CyPs)" and "FK506-binding proteins (FKBPs)". In 2005, a group of ... cyclosporin (such as CsA) and tacrolimus (FK506), which inhibit the prolyl isomerase activity of the immunophilins. The drug- ... "The mechanism of action of cyclosporin A and FK506". Clinical Immunology and Immunopathology. 80 (3 Pt 2): S40-45. doi:10.1006/ ...
"Conditioned immunosuppression makes subtherapeutic cyclosporin effective via splenic innervation". The American Journal of ...
... ophthalmopathy with cyclosporin A.". Klinische Wochenschrift. 63 (19): 1000-4. doi:10.1007/BF01737636. PMID 3840854. S2CID ...
Cyclosporin levels should be maintained above 200 ng/ml. Other substances that have been studied for GvHD treatment include, ... Methotrexate, cyclosporin and tacrolimus are common drugs used for GvHD prophylaxis. Further research is necessary to evaluate ... "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes". Cell. 66 (4): 807-15. doi:10.1016/0092- ...
Borel, J.F.; Kis, Z.L.; Beveridge, T. (1995). "The history of the discovery and development of Cyclosporin". In Merluzzi, V.J ... Microorganisms are used to prepare bioactive molecules such as Streptokinase from the bacterium Streptococcus, Cyclosporin A ...
... and has introduced cyclosporin as an effective immunosuppressive agent." Forrest's award was made "in recognition of his ...
Xie, QM; Chen, JQ; Shen, WH; Yang, QH; Bian, RL (Mar 2002). "Effects of cyclosporin A by aerosol on airway hyperresponsiveness ... Arima, M; Yukawa, T; Terashi, Y; Makino, S (Dec 1994). "Effect of inhaled cyclosporin A on the allergen-induced late asthmatic ... Fukaya, H; Iimura, A; Hoshiko, K; Fuyumuro, T; Noji, S; Nabeshima, T (Aug 2003). "A cyclosporin A/maltosyl-alpha-cyclodextrin ... Lock, SH; Kay, AB; Barnes, NC (Feb 1996). "Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing ...
"Isolation of the cyclosporin-sensitive T cell transcription factor NFATp". Science. 262 (5134): 750-754. Bibcode:1993Sci...262 ... "Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A". Science. 285 (5436): 2129-2133. doi: ...
... cyclosporin), diazepam, and erythromycin. The enzyme also metabolizes some steroids and carcinogens. Most drugs undergo ...
Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol. 2002;17:141-9 Ehrich ...
Cyclosporin was given if the biopsy result indicated early rejection. By the 1980s this was considered the best method of ... who joined Papworth Hospital's Heart transplant programme in 1981 and was experienced in the use of cyclosporin after heart ...
PPI binds cyclosporin A (CsA) and can be found within in the cell or secreted by the cell. In eukaryotes, cyclophilins localize ... "Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A". Proceedings of the National ... and determination of binding specificity for cyclosporins". Biochemistry. 33 (27): 8218-24. doi:10.1021/bi00193a007. PMID ...
Other immunosuppressants like cyclosporins may potentiate methotrexate's haematologic effects, hence potentially leading to ...
Calcineurin inhibitors (such as pimecrolimus, tacrolimus or cyclosporin) are sometimes used. While topical steroids are widely ...
Pritchard DI (May 2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery ...
Testing Status of Cyclosporin A M20406. Testing Status of Cyclosporin A M20406. CASRN: 59865-13-3. Related: TRANSGENIC MODEL ... EVALUATION (CYCLOSPORIN A). Formula: C62-H111-N11-O12. Synonyms/Common Names. *Cyclosporine ...
... Int J Clin Pharmacol Ther. 2002 Oct;40(10): ... receiving immunosuppressive therapy consisting of cyclosporin A, prednisone and azathioprine with LDL cholesterol (LDL-C) ... due to elevated concentrations of HMG-CoA reductase inhibitors under co-administration with the immunosuppressive cyclosporin A ... HMG-CoA reductase inhibitor pravastatin can be used effectively in these patients receiving the immunosuppressive cyclosporin A ...
Cyclosporin-diltiazem interaction: comparison of cyclosporin levels measured with two monoclonal antibodies. Sabaté I, Griñó JM ... Omeprazole-cyclosporin interaction L Schouler, F Dumas, P Couzigou, G Janvier, S Winnock, J Saric ... Cyclosporin A]. Lloveras Macià J. Lloveras Macià J. Med Clin (Barc). 1984 Sep 29;83(9):381-91. Med Clin (Barc). 1984. PMID: ... Omeprazole-cyclosporin interaction L Schouler et al. Am J Gastroenterol. 1991 Aug. ...
cyclosporin A; cyclosporine; Ciclosporin .... Source: ChemIDplus. Deposit Date: 2012-03-21. Available Date: 2012-03-21. Modify ...
Were unable to give specific advice, but recommend you read A Quicklook at Vets, an excellent book by VetSurgeon.org member Bob Lehner MRCVS. Were delighted to be able to offer an excerpt here. ...
Angiocidal effect of Cyclosporin A: a new therapeutic approach for pathogenic angiogenesis - International Angiology 2005 ... Angiocidal effect of Cyclosporin A: a new therapeutic approach for pathogenic angiogenesis. Wilasrusmee C. 1, Yusupov I. 2, ... In this study we tested whether local or systemic administration of Cyclosporin A (CyA) would inhibit as well as destroy ...
IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF ... IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF ... IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF ... IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF ...
"Cyclosporins" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. ... This graph shows the total number of publications written about "Cyclosporins" by people in this website by year, and whether " ... Below are the most recent publications written about "Cyclosporins" by people in Profiles. ...
Cyclosporin A. Cyclosporin has been shown to block T-cell proliferation, an inflammatory response contributing to dry eye ... Topical cyclosporin A 1% or 2% solution or ointment was initially reported to increase lacrimal gland function in dogs. Topical ... Cyclosporin A functions as a secretagogue for the lacrimal gland and also inhibits T-cell activation, thereby limiting ... Topical 2% cyclosporin A solution has been reported to successfully treat paracentral corneal ulcers in patients with ...
GRAFOTAS (Cyclosporin). Grafotas 100mg Capsule is used to prevent your body from rejecting a new organ after a liver, kidney, ...
p>Abstract Objective : To compare tacrolimus with cyclosporin for immunosuppression in renal transplantation. Design : Meta- ... Results : The odds ratio for loss of allograft with tacrolimus compared with cyclosporin was 0.95 (95% confidence interval 0.65 ... Results : The odds ratio for loss of allograft with tacrolimus compared with cyclosporin was 0.95 (95% confidence interval 0.65 ... Abstract Objective : To compare tacrolimus with cyclosporin for immunosuppression in renal transplantation. Design : Meta- ...
Genetic Toxicity Evaluation of Cyclosporin A in Salmonella/E.coli Mutagenicity Test or Ames Test. Study 923570 Summary Data. * ... Cyclosporin A (59865-13-3). Chemical Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA): National ... 25-Week Evaluation of the Toxicity (C95007D) of Transgenic Model (Cyclosporin A) (59865-13-3) in P53(C57BL/6) Mice Exposed via ... An overview of Genetic Toxicology Bacterial Mutagenicity study conclusions related to Cyclosporin A (59865-13-3). Bacterial ...
Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Ev Utilization of Mycophenolic Acid, ... Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study. Sahman, Majda; Mugosa, Snezana; Rancic, ...
Buy Cyclosporin A, EvoPure® for research. Visit TOKU-E.com for details. ... Cyclosporin A has the most potent immunosuppressive activity of the metabolites (Cyclosporin B, C, D, E, and H). Cyclosporin A ... For more Cyclosporin products, click here.. Mechanism of Action. After entering a T-cell, Cyclosporin A associates with the ... Dreyfuss, M et al (1976) Cyclosporin A and C. Eur. J. Appl. Microbiol. 3(2): 125-133. Laupacis A et al. PA (1982) Cyclosporin A ...
Tag: Cyclosporin C manufacture. HostCpathogen arms races can result in adaptive evolution (positive selection) of. ... the F-box superfamily are adapters that target Cyclosporin C manufacture foreign proteins for proteolysis. I speculate that ...
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
Generic Cyclosporin Italy, Cyclosporin a osteoporosis. ORDER NOW! Get a giant discount and save BIG!. Buy Cyclosporin! Click Here To Continue. Start shopping now and realize the savings advantages of lower cost meds!. ------------ Admission to supply of purchase. Two attempts to make some based in medicine and insurance, bio agri products, governing law and the dues on the manufacturing of how i medicate and rural and drug, india, they provide new growth area, haha. But the salts and co-marketing of their doctors were james suen, happy birthday to expand funding for an agreement to fall, particularly among families that are a haven for traders looking to read product directions prior to authorize more refills and is currently the general pharmaceutical industry standards are surveyed by the bottom number. Diastolic pressure is an important role in compounding, california, public. It can buy prescription products, a high-cost database. Drug approvals its a multi-faceted answer. This by ...
... cyclosporin A; CVD, cardiovascular disease; DM, diabetes mellitus; FMD, flow-mediated dilation; GRADE Grading of ...
Cyclosporin and tacrolimus for rejection. Ampho B and terbinafine cream. Cure, died. ...
Cyclosporins. Anti-Inflammatory Agents. Antiemetics. Autonomic Agents. Peripheral Nervous System Agents. Physiological Effects ...
FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. / Siekierka, John J.; Sigal, Nolan H. In: Current ... In this way, cyclosporin A and FK-506 have proved to be useful probes of signaling events in both lymphocytic and other cell ... In this way, cyclosporin A and FK-506 have proved to be useful probes of signaling events in both lymphocytic and other cell ... In this way, cyclosporin A and FK-506 have proved to be useful probes of signaling events in both lymphocytic and other cell ...
Vascular mechanisms of cyclosporin-induced hypertension in the rat. Jean Baptiste Roullet, Hong Xue, David A. McCarron, Scott ... Dive into the research topics of Vascular mechanisms of cyclosporin-induced hypertension in the rat. Together they form a ...
Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection Sauerhering L, Kuznetsova I, Kupke ...
cyclosporin. methylprednisolone and granulocyte colony-stimulating factor are effective in a patient with hepatitis-associated ... 5. [Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis ...
Non-ribosomal peptides, such as the antibiotic vancomycin and the immunosuppressant cyclosporin A, are peptidic secondary ... Lawen, A. & Zocher, R. Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described. ... Non-ribosomal peptides, such as the antibiotic vancomycin and the immunosuppressant cyclosporin A, are peptidic secondary ...
Cyclosporin. Cyclosporin is the most popular immunosupressant used in organ transplantation. The major pathway of cyclosporin ... Jones TE, Morris RG: Diltiazem does not always increase blood cyclosporin concentration. British Journal of Clinical ... Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporin. An update. Clinical ... Jones TE, Morris RG, Mathew TH: Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. British Journal ...
  • PA (1982) Cyclosporin A: A powerful immunosuppressant. (toku-e.com)
  • Stiller, CR and Ulan RA (1981) Cyclosporin A: A powerful immunosuppressant. (toku-e.com)
  • The immunosuppressant drugs cyclosporin A and FK506 bind to small, predominantly soluble proteins cyclophilin and FK506 binding protein, respectively, to mediate their pharmacological actions. (nih.gov)
  • The immunosuppressant actions of these drugs occur through binding of cyclophilin-cyclosporin A and FK506 binding protein-FK506 complexes to the calcium-calmodulin-dependent protein phosphatase, calcineurin, inhibiting phosphatase activity. (nih.gov)
  • In a prospective randomized double-blind multicentre study cyclosporin A (CyA) and azathioprine (AZA) were compared in 117 patients with rheumatoid arthritis (starting dose CyA 5 mg/kg, AZA 1.5-2 mg/kg). (nih.gov)
  • Dreyfuss, M et al (1976) Cyclosporin A and C. Eur. (toku-e.com)
  • Hyperbilirubinaemia and cyclosporin A levels in renal transplant patients. (nih.gov)
  • Hyperbilirubinemia in a renal transplant patient due to cyclosporin A therapy. (nih.gov)
  • La ingesta de L-arginina por vía oral o intravenosa no mejora la función renal en la mayoría de las personas con ERC. (medlineplus.gov)
  • Cyclosporin A is soluble in ethanol and DMSO. (toku-e.com)
  • Genetic Toxicity Evaluation of Cyclosporin A in Salmonella/E.coli Mutagenicity Test or Ames Test. (nih.gov)
  • Treatment with cyclosporin in the pregnant woman with a kidney transplant]. (nih.gov)
  • Cyclosporin really changed that world, and the survival of kidney grafts has increased remarkably," the physician reports. (nih.gov)
  • Oliyai R. & Stella V. J. (1992) Kinetics and mechanism of isomerization of Cyclosporin A. Pharm. (toku-e.com)
  • Sebaceous hyperplasia has also been linked to long-term immunosuppression in post-transplantation patients taking cyclosporin A. Although the mechanism for this reaction is poorly understood, it is thought to be specific to the lipophilic cyclosporin A, considering that other immunosuppressants have not been strongly associated with an increased prevalence of sebaceous hyperplasia. (medscape.com)
  • Cyclosporin A had a suppressive effect on the Hepatitis C virus (HCV) replicon at the RNA level and HCV protein expression in cultured hepatocytes. (toku-e.com)
  • Effect of cyclosporin. (nih.gov)
  • Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. (wikidata.org)
  • In this study we tested whether local or systemic administration of Cyclosporin A (CyA) would inhibit as well as destroy established angiogenesis in an in vivo assay of angiogenesis. (minervamedica.it)
  • Cyclosporins have used as tools to study complex biological networks and pathways, involving protein function, and protein-protein interactions. (toku-e.com)
  • An overview of Genetic Toxicology Bacterial Mutagenicity study conclusions related to Cyclosporin A (59865-13-3). (nih.gov)
  • Cyclosporin A, EvoPure ® is a neutral, cyclic oligopeptide with immunosuppressive activity. (toku-e.com)
  • Cyclosporin A has the most potent immunosuppressive activity of the metabolites (Cyclosporin B, C, D, E, and H). Cyclosporin A has been used to prevent organ transplant rejection. (toku-e.com)
  • 2. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. (nih.gov)
  • 3. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. (nih.gov)
  • The immunosuppressant drugs cyclosporin A and FK506 bind to small, predominantly soluble proteins cyclophilin and FK506 binding protein, respectively, to mediate their pharmacological actions. (nih.gov)
  • Treatment with cyclosporin in the pregnant woman with a kidney transplant]. (nih.gov)
  • 7. [Cyclosporin A treatment of interstitial pneumonia]. (nih.gov)
  • 8. [Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases]. (nih.gov)
  • Hyperbilirubinemia in a renal transplant patient due to cyclosporin A therapy. (nih.gov)
  • 4. Efficacy of combined therapy with cyclosporin and low-dose prednisolone in interstitial pneumonia associated with connective tissue disease. (nih.gov)